Analysis of primate renal, allografts after T-cell depletion with anti- CD3-CRM9

Transplantation

Volumn 66, Issue 1, 1998, Pages 5-13

  Armstrong, Nicholas ^a   Buckley, Patrick ^a   Oberley, Terry ^a   Fechner Jr , John ^a   Dong, Yinchen ^a   Hong, Xuening ^a   Kirk, Allan ^a   Neville Jr , David ^b   Knechtle, Stuart ^a,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; FN18 CRM9; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; IMMUNOTOXIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; FEMALE; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE DEPLETION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RHESUS MONKEY; T LYMPHOCYTE;

EID: 0032528251     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199807150-00002     Document Type: Article

References (49)

1. Neville DM, Scharff J, Hu HZ, et al. A new reagent for the induction of T-cell depletion, anti-CD3-CRM9. J Immunother 1996; 19: 85.
2. Neville DM, Scharff J, Srinivasachar K. In vivo T-cell ablation by holo-immunotoxin directed at human CD3. Proc Natl Acad Sci USA 1992; 89: 2585.
3. Knechtle SJ, Vargo D, Fechner J, et al. FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation 1997; 63: 1.
4. Fechner JH, Vargo DJ, Geissler EK, et al. Split tolerance induced by immunotoxin in a rhesus kidney allograft model. Transplantation 1997; 63: 1339.
5. Solez K, Axelson RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
6. Wood RF. Immunologic monitoring after transplantation. In: Morris PJ, ed. Kidney transplantation principles and practice. London: Grune & Stratton, 1984: 383.
7. Orosz CG. Local cellular immunology of experimental transplant vascular sclerosis. Clin Transplant 1996; 10: 100.
8. Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 1995; 59: 313.
9. Taylor DO, Ibrahim HM, Tolman DR, et al. Accelerated coronary arteriosclerosis in cardiac transplantation. Transplant Rev 1991; 5: 165.
10. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752.
11. Tesi RJ, Elkhammas EA, Henry ML, et al. Acute rejection episodes - best predictor of long-term primary cadaveric renal survival. Transplant Proc 1993; 24: 901.
12. Williams GM, Hume DM, Hudson RP, et al. Hyperacute renalhomograft rejection in man. N Engl J Med 1968; 279: 611.
13. Halloran PF, Schlaut J, Solez K, et al. The significance of the anti-class I response. Transplantation 1992; 53: 550.
14. Trpkov K, Campbell P, Pazderka F, et al. Pathologic features of acute renal allograft rejection associated with donor-specific antibody. Transplantation 1996; 61: 1586.
15. Lobo PI, Spencer CE, Stevenson WC, et al. Evidence demonstrating poor kidney graft survival when acute rejections are associated with IgG donor-specific lymphotoxin. Transplantation 1995; 59: 357.
16. Grace JA, Bolton EM, Porteus C, et al. T cell requirements for the rejection of renal allografts bearing isolated class I disparity. J Exp Med 1990; 172: 1547.
17. Ruiz P, Howell DN, Baldwin WM III, et al. Similarities in long-term alloreactive T cell lines propagated from transfusion enhanced and control-rejecting rat renal allografts. Transplantation 1989; 47: 390.
18. Ruiz P, Coffman TM, Howell DN, et al. Evidence that pretransplant donor blood transfusions prevent rat renal allograft dysfunction but not the in situ cellular alloimmune or morphologic manifestations of rejection. Transplantation 1988; 45: 1.
19. Dallman MJ, Wood KJ, Morris PJ. Specific cytotoxic T cells are found in the nonrejected kidneys of blood-transplanted rats. J Exp Med 1987; 165: 566.
20. Downey WE III, Baldwin WM III, Sanfillipo F. Association of donor-specific blood transfusion enhancement of rat renal allografts with accelerated development of anti-idiotypic antibodies and reduced alloantibody responses. Transplantation 1990; 49: 160.
21. Armstrong HE, Bolton EM, McMillan I, et al. Prolonged survival of actively enhanced rat renal allografts despite accelerated cellular infiltration and rapid induction of both class I and class II MHC antigens. J Exp Med 1987; 164: 891.
22. Wasowska B, Baldwin WM, Howell DN, et al. The effects of donor-specific blood transfusion enhancement of rat renal allografts on cytotoxic activity and phenotypes of peripheral blood lymphocytes, splenocytes, and graft-infiltrating cells. Transplantation 1991; 51: 451.
23. Wood KJ, Hopley A, Dallman MJ, et al. Lack of correlation between the induction of donor class I and class II major histocompatibility complex antigens and graft rejection. Transplantation 1988; 45: 759.
24. Baldwin WM, Rhoton K, Sanfillipo F. IgM and IgG alloantihody production by splenocytes and deposition in rat renal allografts are decreased by donor-specific transfusion. Transplantation 1991; 51: 481.
25. Axelsen RA, Seymour AE, Mathew TH, et al. Glomerular transplant rejection: a distinctive pattern of early graft injury. Clin Nephrol 1985; 25: 1.
26. Maryniak RK, First MR, Weiss MA. Transplant glomerulopathy: evolution of morphologically distinct changes. Kidney Int 1985; 27: 799.
27. Russ GR, Nicholls C, Sheldon A, et al. Positive B lymphocyte crossmatch and glomerular rejection in renal transplant recipients. Transplant Proc 1987; 19: 1875.
28. Knapp LA, Cadavid LF, Eberle ME, et al. Identification of novel Mamu-DRB alleles using DGGE and direct sequencing. Immunogenetics 1997; 45: 171.
29. Li A, Forsum U. Some monoclonal anti-human lymphocyte and class II MHC antigens antibodies do not stain snap frozen Macaco fascicularis lymphocytes or tissue sections. J Med Primatol 1991; 20: 262.
30. Stevens HP, van der Kwast TH, Timmermans A, et al. Monoclonal antibodies for immunohistochemical labeling of immunocompetent cells in frozen sections of rhesus monkey tissues. J Med Primatol 1991; 20: 386.
31. Kirk AD, Bollinger RR, Finn OJ. Rapid, comprehensive analysis of human cytokine mRNA and its application to the study of acute renal allograft rejection. Hum Immunol 1995; 43: 113.
32. Dallman MJ, Wood KJ, Hamano K, et al. Cytokines and peripheral tolerance to alloantigen. Immunol Rev 1993; 133: 5.
33. Nocera A, Cosimi AB, Colvin RB, et al. Function and surface phenotype of T lymphocytes infiltrating renal allografts in nonhuman primates treated with monoclonal antibodies. Transplantation 1989; 48: 732.
34. McLean AG, Hughes D, Welsh KI, et al. Patterns of graft infiltration and cytokine gene expression during the first 10 days of kidney transplantation. Transplantation 1997; 63: 374.
35. Bugeon L, Cuturi MC, Hallet MM, et al. Peripheral tolerance of an allograft in adult rats - characterization by low interleukin-2 and interferon-γ mRNA levels and by strong accumulation of major histocompatibility complex transcripts in the graft. Transplantation 1992; 54: 219.
36. Mottram PL, Han W-R, Purcell LJ, et al. Increased expression of IL-4 and IL-10 and decreased expression of IL-2 and interferon-γ in long-surviving mouse heart allografts after brief CD4-monoclonal antibody therapy. Transplantation 1995; 59: 559.
37. Dallman MJ, Shiho O, Page TH, et al. Peripheral tolerance to alloantigen results from altered regulation of the interleukin-2 pathway. J Exp Med 1991; 173: 79.
38. Wu CJ, Lovett M, Wong-Lee J, et al. Cytokine gene expression in rejecting cardiac allografts. Transplantation 1992; 54: 326.
39. Noronha IL, Eberlein-Gonska M, Hartley B, et al. In situ expression of tumor necrosis factor-alpha, interferon-gamma, and interleukin-2 in renal allograft biopsies. Transplantation 1992; 54: 1017.
40. Nast CC, Zuo X, Danovitch GM, et al. Gamma-interferon expression in human renal allograft fine-needle aspirates. Transplantation 1994; 57: 498.
41. Cunningham DA, Dunn MJ, Yacoub MH, et al. Local production of cytokines in the human cardiac allograft. Transplantation 1994; 57: 1333.
42. Mohler KM, Streilein JW. Lymphokine production by MLR-reactive reaction lymphocytes obtained from normal mice and mice rendered tolerant of class II MHC antigens. Transplantation 1989; 47: 625.
43. Powell TJ, Streilein JW. Neonatal tolerance by class II alloantigens activates IL-4-secreting, tolerogen-responsive T cells. J Immunol 1990; 59: 1571.
44. Shirwan H, Cosenza CA, Wang HK, et al. Prevention of orthotopic liver allograft rejection in rats with a short-term brequinar sodium therapy. Transplantation 1994; 57: 1072.
45. VanBuskirk A, Wakely ME, Orosz CG. Transfusion of polarized TH2-like cell populations into SCID mouse cardiac allograft recipients results in acute allograft rejection. Transplantation 1996; 62: 229.
46. Piccotti JR, Chan SY, VanBuskirk A, et al. Are Th2 helper T lymphocytes beneficial, deleterious, or irrelevant in promoting allograft survival? Transplantation 1997; 63: 619.
47. Alfrey AJ, Most D, Wang X, et al. Interferon-gamma and interleukin-10 messenger RNA are up-regulated after orthotopic liver transplantation in tolerant rats: evidence for cytokine-mediated immune dysregulation. Surgery 1995; 118: 399.
48. Krieger NR, Most D, Bromberg JS, et al. Coexistence of the TH1-and TH2-type cytokine profiles in anti-CD2 monoclonal antibody-induced tolerance. Transplantation 1996; 62: 1285.
49. Lang T, Krams SM, Martinez OM. Production of IL-4 and IL-10 does not lead to immunologic quiescence in vascularized human organ grafts. Transplantation 1996; 62: 776.